Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
CYAD Celyad $21.35 (0.00%) , ADAP Adaptimmune $3.83 -0.06 (-1.54%) … 08:06 03/20/19 03/20 08:06 03/20/19 08:06 Conference/Events	William Blair to hold a conference » 9th Annual Cancer… 9th Annual Cancer Immunotherapy Conference will be held in New York on March 20. CYAD Celyad $21.35 (0.00%) ADAP Adaptimmune $3.83 -0.06 (-1.54%) ADRO Aduro Biotech $3.92 -0.1 (-2.49%) ALLO Allogene Therapeutics $26.25 -0.53 (-1.98%) ATRA Atara Biotherapeutics $39.18 0.02 (0.05%) AUTL Autolus Therapeutics $25.05 0.05 (0.20%) BLCM Bellicum Pharmaceuticals $3.62 0.06 (1.69%) CALA Calithera Biosciences $6.50 -0.08 (-1.22%) DVAX Dynavax $8.00 0.24 (3.09%) FATE Fate Therapeutics $18.00 -0.35 (-1.91%) HARP Harpoon Therapeutics $12.10 0.1 (0.83%) INFI Infinity Pharmaceuticals $1.80 (0.00%) MRK Merck $81.93 0.59 (0.73%) MRUS Merus $12.85 -0.15 (-1.15%) NKTR Nektar $34.40 -0.5 (-1.43%) PFE Pfizer $42.32 0.51 (1.22%) PIRS Pieris Pharmaceuticals $3.22 -0.11 (-3.30%) RCUS Arcus Biosciences $11.64 -0.12 (-1.02%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Mar 20 Mar 20 Mar 04 Apr 08 Apr 09 Apr 09 Apr 11 Apr 30 Apr 30 Apr 18 May 23 May 24 May 17 Jun

Over a week ago
ALLO Allogene Therapeutics $26.48 -0.35 (-1.30%) 17:18 03/14/19 03/14 17:18 03/14/19 17:18 Initiation	Allogene Therapeutics initiated at Raymond James » Allogene Therapeutics… Allogene Therapeutics initiated with an Outperform at Raymond James. Raymond James analyst Dane Leone initiated Allogene Therapeutics with an Outperform rating and a price target of $40. The analyst says the analysis of the company's CAR T cell therapies in UCART19 CALM and PALL study suggests a "competitive profile vs. autologous CD19+ CAR T cell products and supports a positive outlook for ALLO-501". Leone adds that while there are "questions surrounding the correlation of persistence and durable outcomes from the studies", he believes that the "potential to re-dose ALLO-501 balances this risk". 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Mar 20 Mar
ALLO Allogene Therapeutics $26.83 0.11 (0.41%) 09:13 03/14/19 03/14 09:13 03/14/19 09:13 Initiation	Allogene Therapeutics initiated at William Blair » William Blair starts… William Blair starts Allogene with Outperform rating, $37 fair value estimate. William Blair analyst Raju Prasad last night initiated coverage of Allogene Therapeutics with an Outperform rating and $37 fair value estimate. The next phase of growth in the widespread utilization of cell therapies will be catalyzed by the successful development of "off the shelf" modalities, Prasad tells investors in a research note. He views Allogene as a core holding for investors looking for exposure to innovation in this subsector with "derisked initial targets and indications." The company's ALLO-715 has the potential to be first-in-class off-the-shelf B-cell maturation antigen product, says Prasad. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Mar 20 Mar
ALLO Allogene Therapeutics $26.83 0.11 (0.41%) 16:43 03/13/19 03/13 16:43 03/13/19 16:43 Initiation	Allogene Therapeutics initiated at William Blair » Allogene Therapeutics… Allogene Therapeutics initiated with an Outperform at William Blair. William Blair analyst Raju Prasad started Allogene Therapeutics with an Outperform rating. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Mar 20 Mar
ALLO Allogene Therapeutics $26.75 0.03 (0.11%) 16:12 03/13/19 03/13 16:12 03/13/19 16:12 Initiation	Allogene Therapeutics initiated at William Blair » Allogene Therapeutics… Allogene Therapeutics initiated with an Outperform at William Blair 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Mar 20 Mar

ALLO Allogene Therapeutics $29.60 -0.05 (-0.17%) 08:04 03/08/19 03/08 08:04 03/08/19 08:04 Earnings	Allogene Therapeutics reports Q4 EPS (37c), consensus (26c) » As of December 31, 2018,… As of December 31, 2018, Allogene had $721.4M in cash, cash equivalents, and investments. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Mar 19 Mar 20 Mar
ALLO Allogene Therapeutics $31.87 0.73 (2.34%) 08:36 02/20/19 02/20 08:36 02/20/19 08:36 Hot Stocks	Allogene Therapeutics enters lease to develop cell therapy facility » Allogene Therapeutics… Allogene Therapeutics announced that it has entered into a lease agreement to develop a 118,000 square foot cell therapy manufacturing facility in Newark, California. The new manufacturing facility is being designed to provide GMP manufacturing for clinical supply and commercial product upon potential regulatory approval. Allogene currently manufactures its clinical trial supply through a contract manufacturing organization, which continues to remain a component of the company's long-term manufacturing strategy. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
EXEL Exelixis $22.06 0.37 (1.71%) , SPPI Spectrum $11.83 0.21 (1.81%) … 07:41 02/14/19 02/14 07:41 02/14/19 07:41 Conference/Events	Guggenheim to hold a conference » Guggenheim Healthcare… Guggenheim Healthcare Talks Idea Forum Oncology Day will be held in New York on February 14. EXEL Exelixis $22.06 0.37 (1.71%) SPPI Spectrum $11.83 0.21 (1.81%) ALLO Allogene Therapeutics $31.96 0.57 (1.82%) BMY Bristol-Myers $50.97 1.24 (2.49%) FTSV Forty Seven $15.33 0.39 (2.61%) LLY Eli Lilly $119.08 0.27 (0.23%) REPL Replimune Group $13.90 -1.37 (-8.97%) XNCR Xencor $35.87 -0.27 (-0.75%) MRUS Merus $11.94 -0.06 (-0.50%) IOVA Iovance Biotherapeutics $9.79 0.12 (1.24%) FATE Fate Therapeutics $14.73 -0.27 (-1.80%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	14 Feb 14 Feb 18 Feb 28 Feb 02 Apr 18 May 20 May
ALLO Allogene Therapeutics $29.65 1.17 (4.11%) 09:09 01/28/19 01/28 09:09 01/28/19 09:09 Hot Stocks	Allogene Therapeutics announces FDA clearance of ALLO-501 IND » Allogene Therapeutics in… Allogene Therapeutics in collaboration with its development partner Servier announced that the FDA has cleared Allogene's investigational new drug, or IND, application for ALLO-501 in patients with relapsed/refractory non-Hodgkin lymphoma, or NHL. Allogene is the sponsor of the ALLO-501 program. The Phase 1 portion of the study is designed to assess the safety and tolerability at increasing dose levels of ALLO-501 in the most common NHL subtypes of relapsed/refractory diffuse large B-cell lymphoma or follicular lymphoma. ALLO-501 will be administered following lymphodepletion with fludarabine/cyclophosphamide and ALLO-647, Allogene's proprietary anti-CD52 monoclonal antibody. The ALPHA Phase 1 trial will treat up to 24 patients and is on track for initiation in the first half of 2019. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
CELG Celgene $84.92 4.4 (5.46%) , CAH Cardinal Health $44.90 0.75 (1.70%) … 08:10 01/07/19 01/07 08:10 01/07/19 08:10 Conference/Events	JPMorgan to hold a conference » 37th Annual Healthcare… 37th Annual Healthcare Conference will be held in San Francisco on January 7-10. CELG Celgene $84.92 4.4 (5.46%) CAH Cardinal Health $44.90 0.75 (1.70%) MDT Medtronic $88.15 2.76 (3.23%) RUBY Rubius Therapeutics $18.51 0.54 (3.01%) AMAG Amag Pharmaceuticals $16.21 0.62 (3.98%) BDX Becton Dickinson $217.03 5.99 (2.84%) MASI Masimo $106.02 3.33 (3.24%) LLY Eli Lilly $114.65 3.36 (3.02%) BIO Bio-Rad $225.81 1.04 (0.46%) ALLO Allogene Therapeutics $26.40 0.36 (1.38%) DOVA Dova Pharmaceuticals $8.82 0.37 (4.38%) BLUE Bluebird Bio $106.50 6.57 (6.57%) OMCL Omnicell $60.56 1.51 (2.56%) NVDA Nvidia $136.20 8.19 (6.40%) AUPH Aurinia Pharmaceuticals $6.65 0.09 (1.37%) MGNX MacroGenics $13.28 0.69 (5.48%) AFMD Affimed N.V. $3.27 0.19 (6.17%) IOVA Iovance Biotherapeutics $9.52 0.62 (6.97%) ACAD Acadia $17.57 1.41 (8.73%) HQY HealthEquity $58.06 3.25 (5.93%) NKTR Nektar $33.96 2.39 (7.57%) BMY Bristol-Myers $46.88 1.76 (3.90%) BAX Baxter $66.47 2.04 (3.17%) MOH Molina Healthcare $109.71 3.69 (3.48%) WAT Waters $179.68 3.23 (1.83%) NVS Novartis $85.88 1.1 (1.30%) HUM Humana $276.89 7.19 (2.67%) ENTA Enanta $72.49 2.77 (3.97%) GSK GlaxoSmithKline $38.62 0.76 (2.01%) ABT Abbott $68.10 1.87 (2.82%) MCK McKesson $114.41 1.59 (1.41%) UHS Universal Health $118.59 2.72 (2.35%) BOLD Audentes Therapeutics $23.05 1 (4.54%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 08 Jan 08 Jan 08 Jan 08 Jan 08 Jan 14 Jan 15 Jan 16 Jan 17 Jan 23 Jan 24 Jan 27 Jan 28 Jan 30 Jan 31 Jan 25 Feb 23 Mar 18 May 20 May 28 May 30 Jun

On The Fly

News and insights, exclusive to thefly.com

15:06	Bank stocks sit out rally, mirroring concern for broader economy»
13:33	Notable companies reporting after market close»
10:41	Goldman joins seven others in downgrading Biogen on Alzheimer's failure»
10:12	Fly Intel: Top five analyst initiations»
10:12	Fly Intel: Top five analyst downgrades»

View all On The Fly Stories »

Upcoming
Events (10)

ALIT	Alight - ALIT
	Asia Money 20/20
WUBA ...	China Internet Tour
BA ...	Global Industrials and EU Autos Conference
	California Field Trip
	European Financials Conference
BKH ...	West Coast Utilities Conference
	Annual Transports & Industrials Conference
	Financials Conference 2019
	Domopalooza 2019

View all of today’s events »

Today’s
Syndicate (6)

LEVI	IPO
EQH	Secondary
FTDR	Secondary
LQDA	Secondary
TGLS	Secondary
CBMG	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial